Bain Capital Life Sciences Investors’s Tvardi Therapeutics TVRD Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-657	Closed	-$39.7K	–	31
2023 Q3	$39.7K	Sell	657 -25,312	-97%	-$2.37M	﹤0.01%	31
2023 Q2	$2.65M	Sell	25,969 -35,266	-58%	-$4.86M	0.27%	30
2023 Q1	$10.8M	Sell	61,235 -13,655	-18%	-$4.57M	1.35%	21
2022 Q4	$29M	Buy	74,890 +1,349	+2%	+$512K	3.24%	10
2022 Q3	$24.8M	Hold	73,541	–	–	2.96%	11
2022 Q2	$24.2M	Buy	+73,541	New	+$25.8M	2.83%	11

Other funds holding TVRD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bain Capital Life Sciences Investors's TVRD Position: Q4 2023 in Review

Bain Capital Life Sciences Investors sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 657 shares — an estimated $39.7K sold.

Bain Capital Life Sciences Investors first reported a position in TVRD in Q2 2022 and held it in 6 quarters. The position peaked at $29M in Q4 2022. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

Bain Capital Life Sciences Investors reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 657 Tvardi Therapeutics shares in Q4 2023, an estimated $39.7K.
Bain Capital Life Sciences Investors first reported a position in Tvardi Therapeutics in Q2 2022 and held it in 6 quarters.
Bain Capital Life Sciences Investors's Tvardi Therapeutics position peaked at $29M in Q4 2022.
109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2023, filed 13 Feb 2024.